AMENDMENT

IN THE CLAIMS:

Please amend Claims 1 and 77-80 to read as follows.

1. (Amended) A pharmaceutical composition comprising one or more orally deliverable dose units, each comprising particulate celecoxib in an amount of about 10 mg to about 1000 mg in intimate mixture with one or more pharmaceutically acceptable excipients, wherein a single dose unit, upon oral administration to a fasting subject, provides a time course of blood serum concentration of celecoxib having at least one of

(a) a time to reach 100 ng/ml not greater than about 0.5 h after administration;

(b) a time to reach maximum concentration (T_{max}) not greater than about 3 h after administration;

(c) a duration of time wherein concentration remains above 100 ng/ml not less than about 12 h;

(d) a terminal half-life ($T_{1/2}$) not less than about 10 h; and

(e) a maximum concentration (C_{max}) not less than about 200 ng/ml;

said composition exhibiting upon oral administration a relative bioavailability not less than about 50% by comparison with an orally delivered solution containing celecoxib at the same dosage rate.

77. (Amended) The method of Claim 76 wherein, prior to the wet granulating step, the celecoxib is milled to a D_{90} particle size less than about 200 μm, in the longest dimension of said particles.

78. (Amended) The method of Claim 76 wherein, prior to the wet granulating step, the celecoxib is milled to a D_{90} particle size less than about 100 μm, in the longest dimension of said particles.

79. (Amended) The method of Claim 76 wherein, prior to the wet granulating step, the celecoxib is milled to a D_{90} particle size less than about 40 μm, in